BRPI0819828A8 - Processo de síntese de oligômeros de morfolino - Google Patents

Processo de síntese de oligômeros de morfolino

Info

Publication number
BRPI0819828A8
BRPI0819828A8 BRPI0819828A BRPI0819828A BRPI0819828A8 BR PI0819828 A8 BRPI0819828 A8 BR PI0819828A8 BR PI0819828 A BRPI0819828 A BR PI0819828A BR PI0819828 A BRPI0819828 A BR PI0819828A BR PI0819828 A8 BRPI0819828 A8 BR PI0819828A8
Authority
BR
Brazil
Prior art keywords
group
morpholino
synthesis
lower alkyl
morpholin
Prior art date
Application number
BRPI0819828A
Other languages
English (en)
Inventor
Mary Josephine Fox Christina
Dale Reeves Matthew
Li Yongfu
D Weller Dwight
Original Assignee
Avi Biopharma Inc
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avi Biopharma Inc, Sarepta Therapeutics Inc filed Critical Avi Biopharma Inc
Publication of BRPI0819828A2 publication Critical patent/BRPI0819828A2/pt
Publication of BRPI0819828A8 publication Critical patent/BRPI0819828A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

PROCESSO DE SÍNTESE DE OLIGÔMEROS DE MORFOLINO. São fornecidos compostos de morfilino que têm a estrutura (I): em que R¹ é selecionado do grupo que consiste em alquila inferior , di ( alquila inferior) amino e fenila;R² é selecionada do grupo que consiste em alquila inferior , arilmetila monocíclico (arlóxi) metila monocíclico ; R³ é selecionado do grupo que consiste em triarilmetila e hidrogênio ; e Y é selecionado do grupo que consiste em: um grupo hidroxila ou amino protegido ou desprotegido ; um grupo clorofosforamidato ; e uma ligação de fosforodiamidato ao nitrogênio do anel de um composto de morfolino adicional ou de um aligômero de morfolino. Tais compostos incluem monômeros de morfolino guanina (MoG) duplamente protegido. Também é descrito seu uso na síntese de oligômeros de morfolino e outros procedimentos aperfeiçoados para a síntese de oligômeros de morfolino, referente á desproteção do nitrogênio do anel de morfolino protegido em cada etapa de acoplamento do monômero.
BRPI0819828A 2007-11-15 2008-11-14 Processo de síntese de oligômeros de morfolino BRPI0819828A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98819207P 2007-11-15 2007-11-15
US98820007P 2007-11-15 2007-11-15
PCT/US2008/012804 WO2009064471A1 (en) 2007-11-15 2008-11-14 Method of synthesis of morpholino oligomers

Publications (2)

Publication Number Publication Date
BRPI0819828A2 BRPI0819828A2 (pt) 2015-05-26
BRPI0819828A8 true BRPI0819828A8 (pt) 2022-12-27

Family

ID=40293764

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0819828A BRPI0819828A8 (pt) 2007-11-15 2008-11-14 Processo de síntese de oligômeros de morfolino
BR122019021332A BR122019021332A8 (pt) 2007-11-15 2008-11-14 Processo de síntese de oligômeros de morfolino

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019021332A BR122019021332A8 (pt) 2007-11-15 2008-11-14 Processo de síntese de oligômeros de morfolino

Country Status (14)

Country Link
EP (1) EP2207779B1 (pt)
JP (3) JP5512533B2 (pt)
KR (1) KR101617472B1 (pt)
CN (1) CN101861318A (pt)
BR (2) BRPI0819828A8 (pt)
CA (2) CA2884340C (pt)
DK (1) DK2207779T3 (pt)
ES (1) ES2479393T3 (pt)
HK (1) HK1144424A1 (pt)
HR (1) HRP20140646T1 (pt)
IL (1) IL205776A0 (pt)
MX (1) MX2010004955A (pt)
RU (1) RU2606627C2 (pt)
WO (1) WO2009064471A1 (pt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
ES2804764T3 (es) 2009-06-01 2021-02-09 Halo Bio Rnai Therapeutics Inc Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos
TWI495473B (zh) 2009-11-13 2015-08-11 Sarepta Therapeutics Inc 反義抗病毒化合物及治療流感病毒感染的方法
WO2011150408A2 (en) 2010-05-28 2011-12-01 Avi Biopharma, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
SI2623507T1 (sl) 2010-09-30 2017-04-26 Nippon Shinyaku Co.,Ltd. Derivati morfolino-nukleinske kisline
CA2817090A1 (en) 2010-11-12 2012-05-18 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
KR102229650B1 (ko) 2011-05-05 2021-03-19 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
AU2012284259A1 (en) 2011-07-15 2014-03-06 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
KR102142689B1 (ko) * 2011-11-18 2020-08-10 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
WO2013082551A1 (en) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
US10066228B2 (en) 2011-11-30 2018-09-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
WO2013086441A2 (en) 2011-12-08 2013-06-13 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
CA3132111A1 (en) * 2011-12-28 2013-07-04 Nippon Shinyaku Co., Ltd. Antisense nucleic acids for skipping of exon 55 of human dystrophin gene
CA2868174A1 (en) 2012-03-20 2013-09-26 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
US9856474B2 (en) 2013-01-16 2018-01-02 Iowa State University Research Foundation, Inc. Deep intronic target for splicing correction on spinal muscular atrophy gene
JP6477464B2 (ja) * 2013-05-24 2019-03-06 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
CA2922838A1 (en) 2013-09-05 2015-03-12 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
EP3868772A1 (en) 2013-09-30 2021-08-25 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
CA2939948A1 (en) 2014-03-12 2015-09-17 Nippon Shinyaku Co., Ltd. Antisense nucleic acids
AU2015258895A1 (en) 2014-05-16 2016-11-24 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US10391098B2 (en) 2014-05-19 2019-08-27 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
SI3159409T1 (sl) 2014-06-17 2020-02-28 Nippon Shinyaku Co., Ltd. Protismiselna nukleinska kislina za uporabo pri zdravljenju Duchennove mišične distrofije
CN106795186B (zh) * 2014-10-14 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
AU2015372560B2 (en) 2014-12-31 2021-12-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
CN107921092B (zh) 2015-05-19 2022-04-08 萨勒普塔医疗公司 肽寡核苷酸缀合物
MA50829A (fr) 2015-06-01 2018-04-11 Sarepta Therapeutics Inc Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
CN117924364A (zh) * 2015-08-05 2024-04-26 卫材 R&D 管理有限公司 用于制备均一低聚物的手性试剂
CA2995995A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
RS60493B1 (sr) 2015-09-15 2020-08-31 Nippon Shinyaku Co Ltd Antismisaona nukleinska kiselina
US10563199B2 (en) 2015-09-16 2020-02-18 Nippon Shinyaku Co., Ltd. Antisense nucleic acid for treating amyotrophy
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
EA201891419A1 (ru) 2015-12-15 2019-01-31 Сарепта Терапьютикс, Инк. Пептид-олигонуклеотидные конъюгаты
EP3394262A4 (en) 2015-12-23 2019-12-25 Oregon State University ANTISENSE ANTIBACTERIAL COMPOUNDS AND RELATED METHODS
AU2016379399B2 (en) 2015-12-23 2022-12-08 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
MX2018012695A (es) 2016-04-18 2019-06-20 Sarepta Therapeutics Inc Oligomeros antisentido y metodos de uso de los mismos para tratar enfermedades relacionadas con el gen alpha-glucosidasa acido.
EP3449000A1 (en) 2016-04-29 2019-03-06 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
BR112018074270B1 (pt) 2016-05-24 2021-02-02 Sarepta Therapeutics, Inc processo para preparar compostos oligoméricos bem como os ditos compostos
TW201805002A (zh) 2016-05-24 2018-02-16 美商薩羅塔治療公司 磷醯二胺嗎啉代寡聚物醫藥組合物
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA49775A (fr) 2016-05-24 2020-06-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
SG11201809502YA (en) 2016-05-24 2018-12-28 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
AU2017270975B2 (en) 2016-05-24 2021-04-15 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
WO2018057430A1 (en) * 2016-09-20 2018-03-29 The Regents Of The University Of Colorado, A Body Corporate Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
PL3554554T3 (pl) 2016-12-19 2022-12-19 Sarepta Therapeutics, Inc. Koniugaty oligomerów z pominięciem egzonu w dystrofii mięśniowej
HRP20221155T1 (hr) 2016-12-19 2022-12-09 Sarepta Therapeutics, Inc. Oligomerni konjugati koji preskaču egzon za mišićnu distrofiju
LT3554553T (lt) 2016-12-19 2022-08-25 Sarepta Therapeutics, Inc. Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
AU2018256435A1 (en) 2017-04-20 2019-11-07 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MA49986A (fr) * 2017-09-25 2020-07-01 Massachusetts Inst Technology Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
WO2019079637A2 (en) 2017-10-18 2019-04-25 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERIC COMPOUNDS
CA3099778A1 (en) 2018-05-10 2019-11-14 Nippon Shinyaku Co., Ltd. Method for preparing oligonucleic acid compound
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. EXON-SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
SG11202011554PA (en) 2018-06-26 2020-12-30 Nippon Shinyaku Co Ltd Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy
TW202020153A (zh) 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
BR112021011018A2 (pt) 2018-12-13 2021-08-31 Sarepta Therapeutics, Inc. Conjugados de oligômero para exon skipping para distrofia muscular
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
CA3161586A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
JPWO2021095875A1 (pt) 2019-11-13 2021-05-20
MX2022007491A (es) 2019-12-19 2022-08-15 Nippon Shinyaku Co Ltd Acido nucleico antisentido que permite la omision de exones.
AU2020411964A1 (en) 2019-12-26 2022-06-16 National Center Of Neurology And Psychiatry Antisense nucleic acid that induces skipping of exon 50
CA3173049A1 (en) 2020-02-28 2021-09-02 Nippon Shinyaku Co., Ltd. Antisense nucleic acid inducing skipping of exon 51
JP2023541091A (ja) * 2020-07-10 2023-09-28 チャンヂョウ シンザオール ファーマシューティカルズ カンパニー リミテッド オリゴヌクレオチドを調製するための方法
CN117279926A (zh) 2021-04-28 2023-12-22 日本新药株式会社 低聚核酸化合物的制造方法
EP4342498A1 (en) 2021-05-13 2024-03-27 National University Corporation Chiba University Antisense oligomer
KR20240013202A (ko) 2021-05-28 2024-01-30 스미토모 파마 가부시키가이샤 안티센스 핵산
AU2022298028A1 (en) 2021-06-23 2023-12-21 National Center Of Neurology And Psychiatry Combination of antisense oligomers
WO2023282344A1 (ja) 2021-07-08 2023-01-12 日本新薬株式会社 腎毒性軽減剤
CA3225573A1 (en) 2021-07-08 2023-01-12 Nippon Shinyaku Co., Ltd. Precipitation suppressing agent
AU2022306820A1 (en) 2021-07-08 2024-01-04 Nippon Shinyaku Co., Ltd. Nephrotoxicity reducing agent
EP4389893A1 (en) 2021-08-21 2024-06-26 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
EP4387676A2 (en) 2021-09-03 2024-06-26 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
KR20240070615A (ko) 2021-09-30 2024-05-21 사렙타 쎄러퓨틱스 인코퍼레이티드 하나 이상의 비염기성 유닛을 갖는 안티센스 올리고뉴클레오티드
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
WO2023167908A1 (en) * 2022-03-01 2023-09-07 Eisai R&D Management Co., Ltd. Bis-protected, activated guanine monomers
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency
CN117586307B (zh) * 2024-01-19 2024-04-16 凯莱英生命科学技术(天津)有限公司 Pmo鸟苷单体的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH577464A5 (pt) * 1972-09-22 1976-07-15 Ciba Geigy Ag
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
EP0506830B1 (en) * 1989-12-20 2005-12-14 Avi Biopharma, Inc. Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
WO1991018898A1 (fr) * 1990-06-01 1991-12-12 Nippon Shinyaku Co., Ltd. Homologue d'acide nucleique
US5510476A (en) 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
UA48150C2 (uk) * 1994-11-02 2002-08-15 Ай-Сі-Ен Фармасьютикалз Похідні амінокислот або аміноспиртів, олігонуклеотид
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
PL2735568T3 (pl) * 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami

Also Published As

Publication number Publication date
MX2010004955A (es) 2010-06-30
KR20100090681A (ko) 2010-08-16
WO2009064471A1 (en) 2009-05-22
IL205776A0 (en) 2010-11-30
CA2884340A1 (en) 2009-05-22
HK1144424A1 (en) 2011-02-18
JP5512533B2 (ja) 2014-06-04
RU2606627C2 (ru) 2017-01-10
CA2704261C (en) 2015-05-26
CN101861318A (zh) 2010-10-13
ES2479393T3 (es) 2014-07-24
BR122019021332A8 (pt) 2022-12-06
AU2008321409B2 (en) 2014-08-14
BR122019021332A2 (pt) 2015-05-26
RU2010123958A (ru) 2011-12-20
JP2016196494A (ja) 2016-11-24
KR101617472B1 (ko) 2016-05-02
HRP20140646T1 (hr) 2014-09-26
BRPI0819828A2 (pt) 2015-05-26
CA2704261A1 (en) 2009-05-22
EP2207779B1 (en) 2014-04-09
JP2011503184A (ja) 2011-01-27
JP2014159432A (ja) 2014-09-04
JP6178744B2 (ja) 2017-08-09
DK2207779T3 (da) 2014-07-14
EP2207779A1 (en) 2010-07-21
AU2008321409A1 (en) 2009-05-22
CA2884340C (en) 2017-07-25

Similar Documents

Publication Publication Date Title
BRPI0819828A8 (pt) Processo de síntese de oligômeros de morfolino
Correia‐da‐Silva et al. Emerging sulfated flavonoids and other polyphenols as drugs: Nature as an inspiration
Balmond et al. A 3, 4‐trans‐Fused Cyclic Protecting Group Facilitates α‐Selective Catalytic Synthesis of 2‐Deoxyglycosides
ES2528285T3 (es) Molécula de ácido nucleico monocatenario que tiene esqueleto alicíclico que contiene nitrógeno
Wang et al. Biosynthesis of branched alkoxy groups: iterative methyl group alkylation by a cobalamin-dependent radical SAM enzyme
BR0014225A (pt) Derivados de pirazol
BRPI0519759A2 (pt) composiÇÕes farmacÊuticas
JP2009524696A5 (pt)
BRPI0717970B8 (pt) composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto
BRPI0517737A (pt) inibidores de quinase
BRPI0512060B8 (pt) compostos orgânicos, composições farmacêuticas compreendendo os mesmos, bem como uso e processo de preparação dos referidos compostos
BR0112456A (pt) Compostos de piperidina para uso como inibidores de ccr-3
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
BRPI0517033A (pt) novos derivados de hidantoìna como inibidores de metaloproteinase
AR018629A1 (es) Antagonistas de receptor muscarinico, composicion farmaceutica, uso de dichos antagonistas para la manufactura de un medicamento, un metodo paraidentificar compuestos de ligandos multimericos que tiene propiedades multiaglutinantes, una biblioteca de compuestos de ligando multimerico y un metodoiter
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
ZA200801875B (en) Isoquinolines as IGF-IR inhibitors
BRPI0607918A2 (pt) tetraidro-piridoazepin-8-onas e compostos relacionados para o tratemento da esquizofrenia.
SG137667A1 (en) Highly branched (co)polycarbonates having improved flowability
BR0212716A (pt) Inibidores de liberação extracelular de citocinas inflamatórias e composição farmacêutica
NO20055167L (no) Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
ECSP034776A (es) Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos
BR112012007991A2 (pt) inibidores de cxcr1/2 como adjuvantes no transplante de ilhotas pancreáticas
BRPI0518998A2 (pt) âmega-feniloctanamidas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SAREPTA THERAPEUTICS, INC. (US)

B25G Requested change of headquarter approved

Owner name: SAREPTA THERAPEUTICS, INC. (US)